Ohr Pharmaceutical has announced that the first patient has been enrolled in a Phase III clinical trial of the company’s lead drug candidate “Squalamine”, also known as OHR-102, for the treatment of neovascular age-related macular degeneration (wet AMD). “The Phase III clinical program will examine the potential of Squalamine, when administered as part of a combination therapy, [Read More]
Category: Latest News
Smoking and AMD—Are E-Cigarettes the Answer?
by Dan Roberts You’ve heard it before: “Tobacco Smoking Is A Major Cause Of Age Related Macular Degeneration”. According to most research, individuals 65 years of age and over double their risk of developing age-related macular degeneration (AMD) if they smoke. Why? Because tobacco smoking: Reduces levels of plasma antioxidant, a substance in the blood [Read More]
Sleeping Too Much Will *Not* Cause Blindness
Editorial by Dan Roberts Recent research has found an association between longer sleep duration and advanced dry age-related macular degeneration (dAMD), also known as geographic atrophy. This has been misconstrued by at least one media outlet to mean that too much sleep might actually cause the disease. That is absolutely untrue. According to the researchers, “Sleeping [Read More]
Experimental Gene Therapies Still Raising Hopes
Wills Eye Hospital has announced that it has treated the first RESCUE trial patient in the United States enrolled in an FDA-approved gene therapy vision research study. A product called GS010 (GenSight Biologics), can be injected right into the eye and, in a sense, “re-wire” or lower the patient’s risk for getting the disease. The patient has [Read More]
Similarity of Anti-VEGF Drugs Confirmed For DME Treatment
A rigorous clinical trial has found that individuals with diabetic macular edema (DME), whose visual acuity is 20/50 or worse, gained more improvement with Eylea than with Avastin. Aside from that, no significant difference was found among the three anti-VEGF drugs (including Lucentis) in subjects with 20/32 or 20/40 vision at the start of treatment. By two years, 41 percent of participants in the [Read More]